What happened to Juno Therapeutics?
Juno's founders and investors saw a new way to treat cancer, and they ran with it. The Seattle company raised more than $300 million and went public within a year of its launch, ultimately selling for more than $9 billion in 2018 to Celgene.Feb 8, 2022
Juno's founders and investors saw a new way to treat cancer, and they ran with it. The Seattle company raised more than $300 million and went public within a year of its launch, ultimately selling for more than $9 billion in 2018 to Celgene.Feb 8, 2022